Danish biotechnology company Bavarian Nordic has today initiated a clinical study with its vaccine against mpox/smallpox in children 2-12 years old. This is stated in a press release.
The first children have been vaccinated in the Democratic Republic of Congo, with plans to include sites in Uganda. A total of 460 children are expected to participate in the study, which aims to compare the safety and immunogenicity of the vaccine between children and adults.
According to the company, the results of the study could support an expansion of the currently approved vaccine MVA-BN for adults. The vaccine was also pre-qualified last month by the World Health Organization (WHO) for adolescents aged 12-17 years.
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97,2%) and services (2,8%).
Net sales are distributed geographically as follows: the United States (43.2%), Germany (18.6%), France (11.6%), Canada (3.6%), THE United Kingdom (3.4%), Finland (2.9%), Singapore (2.2%), Switzerland (1.7%), Australia (1.3%), Saudi Arabia (1.2%), Spain (0.6%), and others (9.7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
